DARWIN
BRANDS & COMPANIES

BRANDS

NOVODAILY

novodaily.com
Choose from a selection of at-home blood- and DNA tests to find out what your body needs and receive the perfect mixture of nutrients in your personalized supplement packs.

ROOTINE VITAMINS

Try us in the US!
Personalized analyses and supplements to suit your unique requirements.

GENOPEDIA

Browse through our online encyclopedia for genetics and see what our Deep Genome AI engine has gathered from millions of scientific publications as a basis of automated genome analysis.​

COMPANIES

Novogenia

Novogenia GmbH

Salzburg, Austria

100% of Novogenia’s shares are owned by DARWIN AG.

Founded in 2009, Novogenia is one of the leading European companies in nutri genetics and preventive genetic testing. At its headquarters in Salzburg, Austria, Novogenia has built a state of the art medical genetic testing laboratory and has developed novel technologies for the personalization of nutritional supplements and cosmetics based on lab analysis data. The company currently employs a staff of 250 employees. Its 4000m² facility currently houses the laboratory, the supplement and cosmetics manufacture and administration. In 2023-2024, Novogenia will complete its new facility at the same location and increase its production space 3-fold and the Laboratory space 5 fold, with the aim of being able to generate a total of €500 Million of annual revenue at this site.

Novogenia is a service provider for OEM partnerships and develops and distributes its products and services through various B2B channels.

 

Novogenia

Novogenia Marketing GmbH ​

Salzburg, Austria

100% of Novogenia Marketing GmbH shares are owned by DARWIN AG.

Novogenia Marketing GmbH is focused at marketing the products and services of Novogenia to the public. Under the consumer brand NovoDaily, various laboratory analyses (samples collected at home) are offered through omnichannel marketing, leading to a personalized lab data driven nutrient recipe, users can purchase under a subscription plan.

HLN Genetik GmbH

Vienna, Austria ​

DARWIN acquired the controlling majority of HLN Genetik in 2022

Positioned on the highest end of medical genetics, the analysis of embryonic DNA before implantation to boost In Vitro Fertilization success, HLN Genetik is led by Austria’s leading experts in the field of Medical genetics. The laboratory holds the exclusive license for preimplantation genetic testing in Austria and an extensive license for medical diagnostic testing for all genetic diseases known to science. DARWIN acquired the controlling majority of HLN Genetik in 2022 and aims to expand its medical diagnostic portfolio throughout Austria and beyond.

Mendelio

Romania

In the course of incorporation

Mendelio is DARWINs in house software development team. Skilled specialists develop software and artificial intelligence engines for all of DARWINS companies and partners. All Software developed by DARWIN is in house and the IP of DARWIN.

UNIQSANA GmbH​

Germany

DARWIN holds controlling shares of UNIQSANA GmbH

Uniqsana is at the forefront of small scale drug development for an international market. With its Pharma quality sterile laboratories and certifications, medical professionals can produce personalized infusions with ingredients at drug level doses for their patients. Uniqsana is active internationally.

ROOTINE (Claya inc.)

Nashville, USA

DARWIN holds controlling shares of Claya Inc.

Rootine vitamins was cofounded by Daniel Wallerstorfer and was supported by the prestigious TechStars accelerator program in New York. Under the CEO Rachel Sanders (Harvard MBA), Rootine offers at-home lab tests and personalized supplements B2C on the US market. As one of DARWINS fastest growing companies, Rootine has raised its Series A funding of $10 Million in 2022.

NovoMedic GmbH ​

Salzburg, Austria

In the course of incorporation

NovoMedic is a DARWIN in-house Startup specializing in personalized supplement solutions for medical professionals. With a wide portfolio of Novogenia blood and DNA tests, clinicians can offer nutrition relevant testing to their patients. Together with the lab results, clinicians receive a recommended nutrient recipe, that the clinician can adapt with their expertise. The patient receives a subscription based steady supply of personalized supplements.

INVESTMENTS

LykonDX GmbH

Berlin, Germany

DARWIN holds non-controlling shares of Lykon DX.

lykon.com

Positioned on the highest end of medical genetics, the analysis of embryonic DNA before implantation to boost In Vitro Fertilization success, HLN Genetik is led by Austria’s leading experts in the field of Medical genetics. The laboratory holds the exclusive license for preimplantation genetic testing in Austria and an extensive license for medical diagnostic testing for all genetic diseases known to science. DARWIN acquired the controlling majority of HLN Genetik in 2022 and aims to expand its medical diagnostic portfolio throughout Austria and beyond.

SpotKits Inc.

USA

DARWIN holds non-controlling shares in SpotKits Inc.
Spotkits is a B2B service provider for blood tests of customers. SpotKits provides the full service of branded sample kit delivery to the customer, sample transport to the laboratory and submission of test results to the B2B partner. With rapid growth, SpotKits is investing in an in house blood analysis laboratory to improve costs and service quality.

GenomeLink Inc.

USA

DARWIN holds non-controlling shares in GenomeLink Inc.
GenomeLink is a bioinformatics company in the US, offering B2C customers the opportunity to upload their DNA data to gain more insights into their health, traits and ancestry.

Nephrogen Inc.

USA

DARWIN holds non-controlling shares in Nephrogen Inc.
Nephrogen is one of the pioneers in the next revolution in genetic diseases: Correcting congenital genetic defects through gene therapy. The startup is enrolled in the prestigious Y-Combinator Accelerator in the US. Nephrogen’s first target is the genetic disease: Polycystic Kidney Disease (PKD). The aim is to correct the genetic mutation in kidney cells to cure the disease. The investment from DARWIN is a first step into the direction of actual cures for genetic diseases, an inevitable future in the medical field.